GRAL

Based on GRAIL, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does GRAIL do?

GRAIL develops blood-based tests designed to detect cancer signals before symptoms appear. Its lead product, Galleri, screens for multiple cancer types in a single test. The company also offers a diagnostic aid for patients with suspected cancer and is building out post-treatment monitoring tests.

Does GRAL pay dividends?

No, GRAL does not pay a dividend. The company is in an active growth and investment phase, directing capital toward clinical development and commercial expansion of its cancer screening platform rather than shareholder distributions.

When does GRAL report earnings?

GRAIL reports on a quarterly cadence standard for US-listed companies. Because specific upcoming dates are subject to change, check GRAIL's investor relations page for the most current earnings schedule.

Is GRAL a good stock to buy?

UQS Score rates GRAL as Below Average overall. The Growth pillar is Strong and the Risk pillar is Good, but Quality and Moat both rate as Weak, and Valuation is Elevated. Whether that profile suits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.

Is GRAL overvalued?

GRAL's Valuation pillar is rated Elevated by UQS Score, indicating the market is pricing in substantial future growth. For a pre-profit biotech, this is common — but it does mean execution risk is high. View the complete valuation metrics with a Pro account.

How does GRAL compare to its competitors?

GRAIL's closest peers in the diagnostics and genomics space include Neogen Corporation, BillionToOne, and Twist Bioscience. Each pursues different market segments within detection and sequencing technology. GRAIL's specific focus on multi-cancer early detection from a single blood draw is a distinguishing characteristic of its commercial strategy.

What is GRAL's market cap bracket?

GRAL is classified as a mid-cap company. This places it in a range where institutional coverage is growing but liquidity and volatility can differ meaningfully from large-cap healthcare names.

Who founded GRAIL?

GRAIL was spun out of Illumina and incorporated in 2015. Its founding was closely tied to Illumina's leadership and scientific teams focused on applying next-generation sequencing to cancer detection. Detailed founding history is publicly available through GRAIL's corporate disclosures.

Is GRAL a long-term quality investment?

As a long-term quality indicator, GRAL's profile is mixed. The Strong Growth pillar reflects meaningful commercial momentum, but Weak Quality and Moat ratings suggest the business has not yet built durable profitability or a clearly defensible competitive position. Long-term conviction would depend on reimbursement outcomes and clinical adoption trends.

What is the main competitive advantage of GRAIL?

GRAIL's primary differentiation is its Galleri test, which screens for signals from dozens of cancer types in a single blood draw — a capability built on proprietary methylation-based sequencing technology. However, the UQS Moat pillar rates as Weak, reflecting that this advantage has not yet translated into a clearly defensible market position.

What sector does GRAL belong to?

GRAL operates in the Healthcare sector, specifically within the biotechnology and molecular diagnostics industry. Its focus on cancer screening places it at the intersection of genomics, clinical diagnostics, and preventive oncology — a segment attracting significant investment and regulatory attention.

Is GRAL a growth stock or value stock?

Based on its UQS profile, GRAL is firmly a growth-oriented stock. The Growth pillar rates as Strong while the Valuation pillar is Elevated, a combination typical of high-expectation companies where investors are paying a premium for future potential rather than current earnings.

GRAIL, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

GRAIL, Inc. is growing rapidly with strong revenue and earnings expansion.

GRAIL, Inc. maintains a reasonable risk profile with manageable debt levels.

GRAIL, Inc. appears expensively valued relative to its fundamentals and growth prospects.

GRAIL, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GRAL.

The UQS (Unified Quality Score) for GRAIL, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses GRAIL, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether GRAIL, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.